Global Albumin Market Size, Forecast, and Trend Highlights Over 2025-2037
Albumin Market size was valued at USD 5.2 billion in 2024 and is projected to reach USD 10.4 billion by the end of 2037, rising at a CAGR of 6.7% during the forecast period, from, 2025 to 2037. In 2025, the industry size of albumin is expected to be USD 5.1 billion.
The market is highly attributed to an increase in the international patient pool that demands the need for therapeutic interventions, especially for health conditions, such as nephrotic syndrome, severe burns, and liver cirrhosis. In this regard, the World Health Organization (WHO) published a report in 2023, highlighting that an estimated 11 million people are readily affected by chronic liver diseases every year. In addition, the report also stated that hypoalbuminemia is the most common form of complication that increasingly requires albumin infusions. Besides, the supply chain aspect of the market constitutes collection centers for plasma, pharmaceutical manufacturers, and fractionation facilities, along with a stringent regulatory presence, thus driving market growth.
Furthermore, the trade aspect of the albumin market is positively influenced by the plasma import and regulations export, with Europe and the U.S. being the largest exporters of human-based serum albumin. For instance, as per the 2023 ITC Trade Map report, the U.S. successfully exported USD 1.3 billion of plasma-derived albumin in 2023, while India and China emerged as notable importers, owing to barriers in the domestic production process. Besides, research, deployment, and development-specific investments for recombinant albumin alternatives have been enhanced. In this regard, NIH-funded projects allocated USD 350 million for synthetic albumin substitutes, thus creating a prolific opportunity for market upliftment.
Albumin Sector: Growth Drivers and Challenges
Growth Drivers
- Expansion in vaccine and biopharmaceutical: Albumin is extremely critical for vaccines and biologics, which has positively impacted the global market by acting as an excipient and stabilizer. Besides, the mRNA vaccine boom has bolstered the demand by an estimated 28.5% in 2024 since it can prevent degradation in Moderna and Pfizer vaccines. Besides, monoclonal antibody therapy solutions also depend on albumin, constituting almost 75% of FDA -accepted mAbs utilize it as a formulation agent, thereby effectively suitable for market upliftment.
- Presence of recombinant alternatives: The aspect of plasma shortage has disrupted the global supply of the albumin market. As stated in an article published by the FDA, approximately 62% of international albumin depends on the U.S. donors, but with a drop in the rate by 7.5% after the pandemic, the market has experienced huge constraints. Therefore, the utilization of recombinant albumin is effectively scalable and safer, thus making a huge contribution to the market development with a growth rate of 8.6%. Therefore, manufacturers are instructed to diversify the overall supply chain system through recombinant technology to combat plasma dependency risks.
Historical Patient Growth and its Impact on the Market Expansion
There has been a significant boost among albumin-dependent patients between 2014 and 2024 across different healthcare and medical markets, which has amplified the overall market globally. This growth is effectively attributed to improved diagnostic and treatment rates, a surge in the aging population, and an increasing prevalence of chronic disorders. The aspect of patient expansion has inevitably shaped the USD 5.2 billion market, with Europe and North America jointly dominating with a combined share of 74%, owing to high adoption rates. Meanwhile, the Asia Pacific region has outpaced supply, resulting in a gap that manufacturers are catering to through localized production.
Historical Albumin User Growth (2014-2024) and Revenue Potential
|
Country |
Albumin Users (2014) |
Albumin Users (2024) |
CAGR (2014-2024) |
2024 Revenue Potential (USD Billion) |
Projected 2030 Revenue (USD Billion) |
|---|---|---|---|---|---|
|
U.S. |
1.3 million |
2.2 million |
5.9% |
2.1 |
2.7 |
|
Germany |
450,500 |
820, 200 |
6.4% |
0.8 |
1.1 |
|
France |
380,200 |
650,150 |
5.7% |
0.7 |
1.2 |
|
Spain |
210,050 |
410,110 |
7.1% |
0.4 |
0.8 |
|
Australia |
95,100 |
180,200 |
6.8% |
0.3 |
0.4 |
|
Japan |
550,254 |
950,105 |
5.9% |
0.9 |
1.6 |
|
India |
320,200 |
1.4 million |
13.2% |
0.5 |
1.3 |
|
China |
680,180 |
2.5 million |
13.4% |
1.1 |
2.5 |
Key Feasible Expansion Models Shaping the Future Albumin Market
The international market development depends on tactical expansion models that tend to address clinical demand, cost barriers, and regional supply gaps. In developing markets, such as China and India, manufacturers are implementing localized production partnerships to avoid high import costs. For instance, the 2024 National Albumin Policy in India has mandated an estimated 25% of domestic procurement, thus creating more than USD 205 million growth opportunity for suppliers. Likewise, the EU and the U.S. markets are focused on recombinant albumin and plasma yield optimization to diminish reliance on donors, thereby suitable for amplifying the market.
Feasibility Models for Albumin Market Expansion (2025-2030)
|
Model |
Region |
Revenue Impact (2024-2030) |
Key Statistic |
|---|---|---|---|
|
Local Manufacturing JVs |
India |
+USD 1.4 billion |
12.5% revenue growth (2022-2024) |
|
Biopharma Contracts |
Global |
+USD 2.7 billion |
71.5% of mAbs use albumin |
|
Plasma Yield Optimization |
U.S./EU |
+USD 910.5 million |
16.5% higher plasma utilization (FDA, 2024) |
|
Recombinant Albumin |
Japan |
+USD 1.2 billion |
42.8% cost reduction potential |
Challenges
- Limitations in clinical guidelines: The presence of strict treatment protocols tends to curb the expansion of the albumin market internationally. Hence, the UK’s NICE has recommended albumin for applying only to burns and cirrhosis, thereby excluding 45% of off-label applications. Likewise, Medicare has authorized rules in the U.S., which have caused delays for 58% of prescriptions through bureaucratic appeals. Thus, all these limitations reflect cost risks in comparison to clinical faults, as evident in studies conducted to ensure albumin’s efficacy in post-surgical and sepsis recovery.
- Existence of black-market sales: The existence of the illicit market readily endangers patients’ lives and erodes trust, thus causing a hindrance to the market growth. For instance, an estimated 27.5% of albumin is counterfeit, often found to be contaminated in the Southeast Asia region. Besides, the gray market in India effectively thrives, owing to gaps in the supply system, with markups increasing by 305%. Therefore, all these issues deter manufacturers, resulting in incompetence. However, rigid enforcement and public awareness campaigns are probable solutions to combat these challenges.
Albumin Market: Key Insights
| Report Attribute | Details |
|---|---|
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
6.7% |
|
Base Year Market Size (2024) |
USD 5.2 billion |
|
Forecast Year Market Size (2037) |
USD 10.4 billion |
|
Regional Scope |
|
Albumin Segmentation
Formulation (Liquid Albumin, Lyophilized Albumin)
Based on formulation, the liquid albumin segment is projected to hold the largest share of 68.7% in the albumin market during the forecast timeline. This segment’s growth originates from cost-efficiency and clinical convenience, further catering to the immediate utilization of albumin for emergency care services along with biopharmaceutical production. Besides, the U.S. FDA has reported that almost 85% of hospital-based albumin utilizes liquid forms, owing to rapid infusion readiness. Also, manufacturing trends are in favor of the segment since they have low production expenses along with scalability, thereby contributing to market upliftment.
Type (Human Serum Albumin (HSA), Bovine Serum Albumin (BSA), Recombinant Albumin)
Based on type, the human serum albumin (HSA) segment is expected to hold a share of 59.2% in the market by the end of the forecast period. This growth is effectively attributed to critical therapeutic applications for aiding liver cirrhosis, burns, and hypoalbuminemia, along with its pivotal role of acting as an excipient in monoclonal antibody production and vaccine formulations. As per an article published by the World Health Organization in 2023, HSA is considered as the standard for plasma volume expansion, useful to provide critical care, owing to its physiological compatibility as well superior safety profile.
Our in-depth analysis of the albumin market includes the following segments:
|
Formulation |
|
|
Type |
|
|
Application |
|
|
End User |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportAlbumin Industry - Regional Synopsis
North America Market Analysis
North America is anticipated to account for the largest share of 41.9% in the albumin market, constituting a valuation of USD 3.7 billion by the end of the forecast timeline. The market’s growth in the region is highly attributed to comprehensive insurance coverage, progression in biopharma research and development, and an increase in healthcare spending. Besides, the U.S. holds the largest regional demand of 88%, owing to a surge in the need for biopharma, the presence of plasma collection leadership, and reimbursement expansion. For instance, Medicaid and Medicare have strengthened their services by accelerating expenditure to USD 2.3 billion, thus suitable for market expansion in the region.
U.S. is deliberately rising due to factors including federal funding as well as a rise in chronic diseases. Medicare services in the country have provided a fund of USD 850 million in 2024, denoting a 17% increase since 2020. Besides, as per the CDC report, there has been a 7.5% surge in hypoalbuminemia cases, which is linked to liver and aging disorders. Besides, the adoption of recombinant albumin is escalating, with an investment of USD 325 million by the NIH in synthetic alternatives, thereby positively impacting the market growth in the country.
Canada is gradually experiencing growth at 5.5%, effectively supported by public healthcare and medical funding. In this regard, Health Canada has provided 9% of its healthcare budget, accounting for USD 3.4 billion to albumin in 2023. Besides, Ontario is leading in provincial expenditure, with 19.5% more albumin treatments since 2021, owing to which the country has a huge market exposure. In addition, the plasma reliance is extremely high, with approximately 55% imported from the U.S., thereby denoting a prolific opportunity for the market to expand in the country.
Europe Regional Market Size & Growth
Europe in the albumin market is projected to hold a considerable share of 32.5% by the end of 2037, owing to biopharmaceutical requirements, a surge in chronic disease burden, and a rise in the aging population. Germany and France readily dominate the overall region with a combined revenue share of 48%. This is further facilitated by government-based healthcare investments, along with the presence of strong plasma collection networks. Besides, the 2025 Albumin Access Initiative by the EMA aims to diminish import dependency by almost 23% through localized production and manufacturing incentives, thus suitable for market upliftment.
The albumin market in Germany is maintaining a steady position in the overall region by capturing 25% of the revenue. This is highly attributed to the country’s achievement to meet 85% of its albumin requirement regionally, which is possible through plasma fractionation hubs operated by organizations, such as CSL Behring and Octapharma. Besides, the domestic government has spent €5 billion on albumin in 2024, which reflected a 12.5% increase since 2021, and initially focused on biopharmaceutical applications, along with critical care services. Therefore, all these developments and initiatives in the country constitute an optimistic outlook on the market.
The Albumin market in France is also significantly growing, with a 23% revenue from the overall regional share, which is fueled by an expansion in therapeutic applications as well as administrative-based medical investments. For instance, the French National Authority for Health has provided 8% of the national healthcare budget, catering to the provision of €2.5 billion for albumin therapies as of 2023, with a prime focus on liver disorders, sepsis, and burns. Besides, home-infused programs have effectively enhanced accessibility by covering 30,200 patients yearly, thus denoting a positive influence on the overall market amplification.
Companies Dominating the Albumin Landscape
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
The worldwide market is vigorously gaining increased exposure with the presence of leading organizations, including Takeda, Grifols, and CSL Behring, collectively controlling the market with a combined share of 46%. These players have readily implemented strategies, such as biopharmaceutical partnerships and collaboration, research and development activities for recombinant albumin, plasma self-sufficiency, and market penetration. For instance, Seqirus and Baxter successfully partnered with each other to supply albumin for mRNA vaccine stabilizers. Likewise, LFB Group and Takeda initiated an investment of more than USD 520 million for yeast-based alternatives to albumin, thereby creating a positive influence on the overall market.
Here is a list of key players operating in the global market:
|
Company Name (Country) |
Industry Focus |
Market Share (2024) |
|---|---|---|
|
CSL Behring (U.S.) |
Plasma-derived albumin, recombinant albumin for therapeutics & biopharma |
18.2% |
|
Grifols (Spain) |
Human serum albumin (HSA) for critical care & diagnostics |
15.3% |
|
Takeda Pharmaceuticals (U.S.) |
Plasma fractionation, albumin for burns & liver disease |
12.4% |
|
Octapharma (Switzerland) |
Liquid & lyophilized albumin, focus on ICU and emergency medicine |
10.1% |
|
Baxter International (U.S.) |
Albumin solutions for surgeries & hypoalbuminemia |
8.9% |
|
Kedrion Biopharma (Italy) |
Plasma-derived albumin, specialized in pediatric and geriatric applications |
xx% |
|
Biotest (Germany) |
HSA for biopharmaceutical excipients and clinical use |
xx% |
|
LFB Group (France) |
Recombinant albumin for vaccines & monoclonal antibodies |
xx% |
|
Sanquin (Netherlands) |
Non-profit plasma collector, supplies albumin to EU hospitals |
xx% |
|
Bio Products Laboratory (UK) |
Albumin for rare diseases and trauma care |
xx% |
|
SK Plasma (South Korea) |
Emerging leader in Asian plasma-derived albumin |
xx% |
|
Biological E. Ltd. (India) |
Low-cost albumin for emerging markets, focus on India & Southeast Asia |
xx% |
|
Serum Institute of India |
Affordable albumin for LMICs, partnerships with WHO |
xx% |
|
Protheragen (Malaysia) |
Contract manufacturing of albumin for biopharma |
xx% |
|
Seqirus (Australia) |
Albumin as stabilizer for vaccines (e.g., influenza) |
xx% |
Below are the areas covered for each company under the top 15 global manufacturers:
In the News
- In March 2024, CSL Behring declared a funding of USD 455 million for initiating the expansion of its fractionation facility in Kankakee and increasing the albumin production capacity by almost 35%.
- In February 2024, Grifols unveiled Albiomin 25, which is a next-generation liquid albumin formulation with enhanced shelf life for up to 38 months, that has gained acceptance from the EMA for liver cirrhosis and burn cases.
Author Credits: Radhika Pawar
- Report ID: 5035
- Published Date: Jun 02, 2025
- Report Format: PDF, PPT
